Sandoz

The Department of Justice on Tuesday indicted Teva Pharmaceutical Industries Ltd’s (NYSE: TEVA) United States unit for conspiring to fix prices, rig bids, and colluding with other companies to allocate customers for generic drugs. What Happened: The indictment filed in the...

Pharmaceutical giant Novartis AG's (NYSE: NVS) subsidiary Sandoz Inc. has agreed to pay $195 million in penalties to avoid facing criminal charges in a price-fixing case, the Justice Department announced Monday. What Happened The New Jersey-based pharmaceutical company was charged with...

Tilray Canada, a subsidiary of medical cannabis company Tilray Inc (NASDAQ: TLRY), entered into a global collaboration agreement with Sandoz AG, a generic pharmaceuticals and biosimilars company that's part of Novartis AG (NYSE: NVS). The agreement marks an expansion of an existing relationship...

Canadian cannabis producer Tilray Inc. (NASDAQ: TLRY) surged Tuesday morning on the announced partnership with pharmaceutical giant Novartis AG (NYSE: NVS). What Happened Tilray said that its subsidiary, Tilray Canada, has entered into an agreement with Sandoz AG, part of the Novartis AG. Under the...

Shares of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) soared higher by 60 percent early Monday morning in reaction to a new partnership with Novartis AG (ADR) (NYSE: NVS). What Happened Adamis, a specialty biopharmaceutical company that focuses on treatments for respiratory diseases and...

Coherus Biosciences Inc (NASDAQ: CHRS) shares were down steeply in pre-market trading after the company announced it has received a complete response letter from the FDA for its abiologic license application, or aBLA, for CHS-1701, a pegfilgrastim biosimilar candidate to Amgen, Inc. (...

Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...

Bernstein's Aaron Gal initiated Amgen, Inc. (NASDAQ: AMGN) at Market Perform and set a price target of $161. The company will have a hard time offsetting "stiff biosimilar headwinds," Gal noted. Amgen has a very old drug portfolio with G-CSFs, ESAs and Enbrel accounting for over 100 percent of its...

Shares of Theravance Inc (NASDAQ: THRX) fell more than 12 percent Wednesday morning after the company's commercial partner, GlaxoSmithKline plc (ADR) (NYSE: GSK), disclosed topline results from SUMMIT. Theravance's trial attempted to prove survival benefits for Breo in COPD patients and failed to...